Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 69.48B |
| Revenue (ttm) | 14.20B |
| Net Income (ttm) | 4.41B |
| Shares Out | 107.02M |
| EPS (ttm) | 38.34 |
| PE Ratio | 16.95 |
| Forward PE | 15.25 |
| Dividend | $0.88 (0.14%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 222,780 |
| Open | 662.45 |
| Previous Close | 661.00 |
| Day's Range | 648.82 - 661.00 |
| 52-Week Range | 642.00 - 1,211.20 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 990.84 (+52.62%) |
| Earnings Date | May 1, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $990.84, which is an increase of 52.62% from the latest price.
News
Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Inves...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to i...
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmace...
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most disti...
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fe...
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline SAN FRANCISCO, CA / ACCESS Newswire / March 5, 2025 / Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is facing h...
Inclusion Body Myositis Pipeline Market Landscape Report 2025 Featuring Abcuro, Regeneron Pharmaceuticals, and Vandria
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into ...
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) TD Cowen 45th Annual Health Care Conference March 4, 2025 11:50 AM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR Conferen...
NASDAQ:REGN Lawsuit Notice: Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Should Contact the Shareholders Foundation
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and continue to hold ...
DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025
PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or th...
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK , March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN dur...
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you ...
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmiss...
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in f...
REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceut...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025
Why Regeneron's Price May Soon Break Out
On February 4, Regeneron released financial results for the fourth quarter of 2024, which beat my and Wall Street analysts' expectations. The main contributors to its revenue and operating income grow...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you ...